OK, the "big news" is probably Regeneron Phase 1 r

OK, the "big news" is probably Regeneron Phase 1 result.

https://clinicaltrials.gov/ct2/show/NCT04426695

This is a phase 1-2-3 clinical trial of REGN10933+REGN10987 dual antibody cocktail for the treatment of hospitalized covid19 patients.

The critical primary endpoint is day 29 seven point scale ranging from not hospitalized to passed away. The seven point scale is: 1) not hospitalized 2) hospitalized, no oxygen and no further medical care needed 3) hospitalized no oxygen needed but further medical care needed 4) hospitalized oxygen needed 5) hospitalized high flow oxygen needed 6) hospitalized ventilation needed 7) passed away

The trial began enrollment on June 10 so the first patient would have gotten through day 29 around July 10. Probably the phase 1 is about 30 patients. So right about now the phase 1 patients are likely through the 29 day period.

So minimum one week to maximum two weeks to analyze the phase 1 data?

This is consistent with the white statements about therapeutic news in the "coming days".

The main challenge for this therapy is that antibody treatments will cause the virus to mutate and escape the antibody. REGN10933 and REGN10987 are antibodies that both target the spike protein but their binding domains do not overlap. Regeneron test tube experiments showed that the virus will quickly mutate and escape if you use only one antibody or if two antibodies with overlapping binding sites.

https://clinicaltrials.gov/ct2/show/NCT04426695